Most acquisition advice for UK telehealth brands focuses on paid social and organic content, and understandably so: those channels are easier to control. Affiliate and partner referral channels get less airtime, largely because a third party writes the copy and the compliance stakes rise accordingly. Done properly, though, this channel often produces some of the cheapest, highest-intent traffic in the vertical.
Why partner channels get skipped
Guides to UK telehealth customer acquisition tend to stop at paid versus organic, because both sit inside the brand's own marketing team and can be signed off before anything goes live. A partner-run comparison site or affiliate blog does not offer that comfort: the brand pays for the traffic without writing the words that generate it.
That discomfort is reasonable, but it is not a reason to skip the channel entirely. With the right agreement and review process in place before launch, partner referral traffic tends to convert well precisely because the visitor arrives already comparing options rather than being interrupted mid-scroll.
The partner-channel types that actually work
Not every affiliate model suits a regulated medicines business. The ones that hold up in practice tend to fall into a handful of categories, each with a different risk profile.
- Independent comparison and review sites covering telehealth or a specific condition
- Clinician and allied-health referral partnerships, where a physiotherapist, dietitian or optician points patients toward a relevant service
- Co-branded employer and insurer wellness schemes, run through a benefits platform rather than open affiliate signup
- Content-affiliate publishers with an established health vertical and an editorial process
- Complementary-service partnerships, such as a fertility app or menopause community referring into HRT or women's-health services
Open affiliate networks with unvetted, high-volume publishers are the hardest to control and the most likely to generate a compliance headache, so most operators restrict signup to an approval step rather than self-serve enrolment.
The rules that apply to your affiliates too
Prescription-only medicines cannot be advertised directly to the public under the Human Medicines Regulations 2012, and that restriction does not disappear because a comparison site or affiliate wrote the copy instead of the brand's own team. A partner page can promote the consultation and the service; it cannot promote the medicine by name with claims aimed at the public.
CAP Code principles hold the marketer, meaning the brand paying for the placement, accountable for what its affiliates publish. An unapproved claim on a partner's page becomes the brand's problem with the ASA, not just the partner's, which is why marketing compliance reviews need to extend to every channel a brand pays for, not only the ones it directly controls.
Affiliate and partner content is the brand's compliance problem too: CAP Code principles hold the marketer paying for the placement accountable for what every partner publishes, not just the partner itself.
Commission structures and the volume-incentive problem
Cost-per-acquisition, revenue share and hybrid retainer-plus-CPA are the three commercial structures most partner agreements settle on. CPA is simplest to reconcile; revenue share suits partners who can drive repeat, longer-term relationships rather than one-off traffic spikes.
The structural risk sits in what the commission is paid on. Paying a pure per-prescription CPA can, in effect, reward a partner for pushing a visitor toward a particular medicine rather than toward an appropriate consultation. Many compliance-conscious operators instead pay on a qualified signup or a completed clinical assessment, which keeps the commercial incentive pointed at lead quality rather than at a prescribing outcome, and prescriber discretion applies regardless of how a patient arrived.
Vetting and onboarding a partner before the first click
The review work belongs before launch, not after a complaint arrives. A short, consistent checklist keeps this manageable even as the partner list grows.
- Request draft creative and landing-page copy before the partnership goes live
- Confirm the partner will not name specific medicines in claims aimed at the public
- Agree a take-down SLA for any content flagged as non-compliant
- Require the partner to link back to accurate product and safety information rather than restating it themselves
- Set data-sharing terms that satisfy UK GDPR lawful-basis requirements before any patient data changes hands
- Get sign-off from whoever owns compliance internally before the first click goes live
A partner optimising for volume can quietly pull down average patient lifetime value even while its nominal cost per acquisition looks attractive next to paid channels.
Measuring a channel that resists last-click attribution
Partner traffic often arrives with inconsistent UTM tagging and a longer consideration window than paid social. Unique per-partner codes help, but comparison sites frequently strip query parameters on the way through, so most operators end up leaning on partner-level cohort tracking (signups per partner per week) rather than trying to force a clean last-click view.
Quality matters more than the headline CAC figure. A partner optimising purely for volume can quietly pull down average patient lifetime value even while its nominal cost per acquisition looks attractive next to paid channels, which is why retention by source, not just acquisition cost by source, belongs in the monthly review.
Where the dispensing layer fits
Whichever channel brings a patient through the door, the dispensing side has to absorb it without a different SLA for each traffic source. That is the operational argument for building on a platform like PExpo before scaling a new partner channel: the fulfilment layer stays constant even as the acquisition mix changes.
PExpo does not run an affiliate programme itself, and the compliance vetting above still sits with the brand. What it does is keep the regulated dispensing infrastructure behind every channel consistent, so testing a new comparison site or referral partner does not mean re-plumbing fulfilment to support it. See pricing for how that layer is structured.
Affiliate and partner referral channels are not a shortcut around the harder work of paid and organic acquisition, but they are a legitimate third leg once the compliance and commission structure is right. Vet before launch, pay on lead quality rather than prescribing outcome, and track retention by source so a cheap-looking channel does not turn out to be an expensive one. If you are weighing up a new partner channel against your current dispensing setup, get in touch.
Frequently asked questions
Is affiliate marketing legal for UK telehealth and prescription medicine brands?
Yes, with caveats. Prescription-only medicines cannot be advertised directly to the public regardless of who publishes the content, so affiliate pages need to promote the consultation and service rather than name specific medicines in public-facing claims. The brand remains accountable for the compliance of every partner it pays, so this needs the same review rigour as in-house marketing.
Can a UK telehealth brand pay affiliates per completed prescription?
Technically it is possible, but most compliance-conscious operators avoid a pure per-prescription CPA because it can implicitly reward a partner for pushing volume toward a prescribing outcome rather than toward an appropriate consultation. Paying on a qualified signup or completed clinical assessment keeps the incentive on lead quality instead, and prescriber discretion applies throughout regardless of the acquisition channel.
How do brands stay ASA-compliant when a partner writes their own ad copy?
Pre-approve creative and landing-page copy before a partnership goes live, keep a written agreement that references CAP Code compliance and a take-down SLA, and periodically monitor what is actually live rather than only what was originally approved. Responsibility sits with the brand paying for the promotion, not solely with the partner who wrote it.
